AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today provided an
update on the STAR trial and announced that it has completed additional
pre-clinical and clinical studies to...
AVANIR Pharmaceuticals (NASDAQ: AVNR) today announced that it has
completed targeted enrollment of patients into the STAR trial, a
confirmatory Phase III trial of Zenvia™...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Avanir Pharmaceuticals (NASDAQ: AVNR) today provided updates on its two license and collaboration agreements and announced certain restructuring...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced that Keith A. Katkin has been appointed President and CEO and elected as a member of the board...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced the Company has met with U.S. Food and Drug Administration (FDA) officials to address concerns...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced that management will provide an update on its meeting with the U.S. Food and Drug...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced that Martin J. Sturgeon has joined the Company as Vice President and Chief Accounting Officer...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) will webcast its quarterly
conference call on Friday, February 9, 2007, at 8:00 a.m. Pacific/11:00
a.m....
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today reported unaudited financial
results for the quarter and fiscal year ended September 30, 2006.
Fourth...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ: AVNR) announced today that the Company
has been selected for addition to the NASDAQ Biotechnology Index, which
will be...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) will be presenting at Lazard
Capital Markets 3rd Annual Life Sciences
Conference on Tuesday, November 28, 2006 at 8:30...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company
has enrolled the targeted number of patients needed to assess the
efficacy endpoint...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that it has taken
several steps intended to significantly reduce ongoing operating
expenses. Effective...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced that it has completed the
previously announced sales of 5,263,158 shares of Class A common stock
at a price...
SAN DIEGO--(BUSINESS WIRE)--Avanir Pharmaceuticals (NASDAQ:AVNR) announced that it has entered into
definitive purchase agreements with institutional investors for the
offering of...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) will webcast its quarterly
conference call on Monday, December 11, 2006 at 8:00 a.m. Pacific /
11:00 a.m. Eastern. The...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced that it has received an
approvable letter from the U.S. Food and Drug Administration (FDA) for
Zenvia™...
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) will be presenting at CIBC World
Markets 17th Annual Healthcare Conference on
Tuesday, November 7, 2006 at 3:35 p.m....
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that results of a
Phase II clinical trial evaluating escalating doses of Neurodex™
in the...
SAN DIEGO--(BUSINESS WIRE)--Sept. 14, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR) will be presenting at the 2006 UBS Global Life Sciences Conference on Wednesday, September 27, 2006 at 11:30 a.m....
SAN DIEGO--(BUSINESS WIRE)--Aug. 23, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR) will be presenting at the ThinkEquity Partners 4th Annual Growth Conference on Tuesday, September 12, 2006 at 1:30...
SAN DIEGO--(BUSINESS WIRE)--Aug. 9, 2006--AVANIR Pharmaceuticals (NASDAQ: AVNR) today reported unaudited financial results for the Company's fiscal third quarter ended June 30, 2006. Third Quarter...
SAN DIEGO--(BUSINESS WIRE)--Aug. 7, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that Theresa Hope-Reese has joined the Company as Vice President of Human Resources. Ms. Hope-Reese...
SAN DIEGO--(BUSINESS WIRE)--Aug. 2, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR) will be presenting at the Bank of America Specialty Pharmaceuticals Conference on Thursday, August 10, 2006 at 8:45...
SAN DIEGO--(BUSINESS WIRE)--July 19, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR) will webcast its quarterly conference call on Wednesday, August 9, 2006 at 1:30 p.m. Pacific/4:30 p.m. Eastern. The...
SAN DIEGO--(BUSINESS WIRE)--July 6, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that it has signed an exclusive agreement with Healthcare Brands International (HBI) to develop and...
SAN DIEGO--(BUSINESS WIRE)--June 30, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced it has been awarded a $2 million grant from the National Institutes of Health/National Institute of...
SAN DIEGO--(BUSINESS WIRE)--June 29, 2006--AVANIR Pharmaceuticals (NASDAQ: AVNR) will be presenting at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, July 11, 2006...
